Daiichi Sankyo joins norovirus vaccine race through UMN alliance
This article was originally published in Scrip
Executive Summary
A new collaborative research agreement with the Japanese bioventure UMN Pharma signals an increasing interest in vaccines on the part of Daiichi Sankyo, following on from several steps it has taken over the past few years to raise its participation in the sector.